CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x June 30, 2010

[FORM 10-Q (Mark One) x June 30, 2010 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [AMENDED AND RESTATED CHARTER cphi10qex31063010.htm 2 EX-3.1] [EMPLOYMENTREEMENT WITNESSETH: WHEREAS, thempany is engaged in the business of develop, manufacture, and marketecialty pharmaceutical products in China (the business); and WHEREAS, Employee has represented that he has the experience, background and expertise necessary to enable his to be thempanys Chief Financial Officer; and WHEREAS, based on such representation, and thempanys reasonable due diligence, thempany] [CHINA PHARMAS, 2010 SHARES OPTIONREEMENT China Pharmas, Frank Waung This 2010 Shares Optionreement (thereement) is made of April 28, 2010 between 1. Notice of Shares Option Grant You (the Optionee) have been granted an option to subscribe for, acquire and purchasemmon shares in thempany (themmon Shares), subject to the terms andnditions of the Plan of] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 9, 2010 -------------------------------- President and Chief Executive Officer cphi10qex321063010.htm 11 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 9, 2010 --------------------- (principal financial officer and principal accounting officer) cpho10qex322063010.htm 12 EX-32.2]

By | 2016-02-07T23:25:46+00:00 August 9th, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] 6-K: WuXi PharmaTech (Cayman) Inc. Form 6-K Press Release

[WuXi PharmaTech (Cayman) Inc. Form 6-K Press Release dated July 29, 2010 99.1 Termination Agreement dated as of July 29, 2010 between WuXi PharmTech (Cayman) Inc. and Charles River Laboratories International, Inc. 99.2 WuXi PharmaTech (Cayman) Inc. E I]

By | 2016-04-02T19:16:51+00:00 July 30th, 2010|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] CORRESP: (Original Filing)

[瑞生國際律師 事 務 所 41st Floor, One Exchange Square 8 Connaught Place, Central Hong Kong Tel: +852.2522.7886 Fax: +852.2522.7006 www.lw.com 香港中環康樂廣場八號交易廣場第一座 四十一樓 FIRM / AFFILIATE OFFICES Abu Dhabi Moscow Barcelona Munich Beijing New Jersey Brussels New York Chicago Orange County Doha Paris July 22, 2010 Dubai Riyadh Frankfurt Rome Hamburg San Diego VIA EDGAR Hong Kong San Francisco]

By | 2016-03-24T02:47:17+00:00 July 22nd, 2010|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] CORRESP: 瑞生國際律師 事 務 所 41st Floor, One Exchange

[瑞生國際律師 事 務 所 41st Floor, One Exchange Square 8 Connaught Place, Central Hong Kong Tel: +852.2522.7886 Fax: +852.2522.7006 www.lw.com 香港中環康樂廣場八號交易廣場第一座 四十一樓 FIRM / AFFILIATE OFFICES Abu Dhabi Moscow Barcelona Munich Beijing New Jersey Brussels New York Chicago Orange County Doha Paris July 22, 2010 Dubai Riyadh Frankfurt Rome Hamburg San Diego VIA EDGAR Hong Kong San Francisco]

By | 2016-03-24T02:48:32+00:00 July 22nd, 2010|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Holds 2010 Annual Meeting of Shareholders Beijing — July 15, 2010 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines in China, announced today that it held its 2010 Annual Meeting of Shareholders on Thursday, July 15, 2010 at 9:00 a.m. Beijing Time. The required quorum, a majority of the common shares outstanding, was voted] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T02:49:58+00:00 July 19th, 2010|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Holds 2010 Annual Meeting of Shareholders Beijing

[Sinovac Holds 2010 Annual Meeting of Shareholders Beijing — July 15, 2010 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines in China, announced today that it held its 2010 Annual Meeting of Shareholders on Thursday, July 15, 2010 at 9:00 a.m. Beijing Time. The required quorum, a majority of the common shares outstanding, was voted] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T02:50:56+00:00 July 19th, 2010|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar